Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced that its project to advance a robotic aseptic fill and finish platform has been approved for expanded support by the Israel Innovation Authority, allowing the company to utilize the full approved grant budget of NIS 5 million over two years. Approximately 66% of this funding is non-dilutive, representing a significant financial advantage for the company's capital allocation strategy.
The program specifically supports the acquisition and validation of a fully automated robotic-arm aseptic fill and finish system that aligns with EU GMP Annex 1 standards, with validation targeted for completion by the third quarter of 2026. This timeline positions Scinai to meet growing industry demand for advanced sterile manufacturing capabilities as biologics and complex therapies continue to dominate pharmaceutical development pipelines.
This investment supports Scinai's broader contract development and manufacturing organization expansion strategy, which has been strengthened through its acquisition of Recipharm Israel Ltd. and commercial collaboration with Recipharm. The company operates two manufacturing sites in Israel: a biologics development and clinical manufacturing facility in Jerusalem and a small-molecule API development and GMP manufacturing site in Yavne. Through its strategic commercial collaboration agreement with Recipharm, Scinai offers clients a defined pathway from early clinical development to late-stage and commercial manufacturing within Recipharm's global network, enabling continuity of development and reduced scale-up risk.
The expanded grant approval is particularly significant for the biotechnology industry as it demonstrates government support for advanced manufacturing technologies that can improve drug safety, reduce contamination risks, and increase production efficiency. The robotic aseptic fill and finish platform addresses critical challenges in sterile manufacturing, where manual processes have traditionally presented higher risks of contamination and variability. By implementing automated systems aligned with EU GMP Annex 1 standards, Scinai positions itself to serve both domestic Israeli biotech companies and international clients seeking high-quality manufacturing solutions.
For investors and industry observers, this development highlights Scinai's disciplined approach to capital allocation through maximized non-dilutive funding while expanding its service offerings. The company's CDMO unit provides fee-for-service development and manufacturing solutions to biotech and pharmaceutical companies, supporting external clients from preclinical development through Phase I/II clinical supply. This includes biologics process development, analytical method development, sterile fill and finish, clinical cGMP manufacturing, and small-molecule API process development and optimization.
Parallel to its CDMO operations, Scinai continues to advance its focused immunology pipeline through its R&D unit, including PC111, a first-in-class anti-FasL monoclonal antibody targeting orphan dermatologic indications, and next-generation NanoAb-based programs in inflammation. The company is seeking strategic partnerships, co-development agreements, and regional licensing opportunities to advance selected programs toward clinical validation. The latest news and updates relating to SCNI are available in the company's newsroom at https://ibn.fm/SCNI.
